SCHEMBL598166

SCHEMBL598166

Cc1cc(N)cc(C)c1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.50
ACHE P22303 1/20 0.50
KDM4E B2RXH2 5/20 0.48
KMT2A Q03164 5/20 0.48
MEN1 O00255 3/20 0.48
TDP1 Q9NUW8 1/20 0.48
ALDH1A1 P00352 5/20 0.47
MAPK1 P28482 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 3/20 0.42
TPMT P51580 1/20 0.42
NOTUM Q6P988 1/20 0.41
LDHA P00338 2/20 0.41
LDHB P07195 2/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL2892582 0.95 CYP3A4 (0.47) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL8618720 0.89 KDM4E (0.53) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL27739144 0.87 KDM4E (0.57) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL13083103 0.87 CYP3A4 (0.64) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL15233200 0.85 ALDH1A1 (0.48) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL20670043 0.83 POLB (0.39) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL2380085 0.80 THRB (0.43) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL21870 0.79 KDM4E (0.55) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL377596 0.79 KDM4E (0.55) CYP3A4ACHEKDM4EKMT2AMEN1
SCHEMBL900744 0.79 CYP3A4 (0.54) CYP3A4ACHEKDM4EKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799791-B1 PHOTOCROSSLINKABLE MATERIALS ROLIC AG (CH) 2016-01-13 EP claimed
US-7687118-B2 Photocrosslinkable materials ROLIC AG (CH) 2010-03-30 US claimed
US-20080069968-A1 Photocrosslinkable Materials ROLIC AG (CH) 2008-03-20 US claimed
EP-1799791-A1 PHOTOCROSSLINKABLE MATERIALS Rolic AG (CH) 2007-06-27 EP claimed
WO-2006039824-A1 PHOTOCROSSLINKABLE MATERIALS ROLIC AG (CH) 2006-04-20 WO claimed
US-20250180952-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2025-06-05 US disclosed
EP-4493638-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2025-01-22 EP disclosed
CN-118871548-A Photoalignment materials 罗利克技术有限公司 2024-10-29 CN disclosed
CN-118027412-A Photo-alignment material 罗利克技术有限公司 2024-05-14 CN disclosed
WO-2023174773-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2023-09-21 WO disclosed
US-11634544-B2 Photoaligning materials Rolic Technologies AG (CH) 2023-04-25 US disclosed
US-20210340330-A1 PHOTOALIGNING MATERIALS Rolic Technologies AG (CH) 2021-11-04 US disclosed
EP-1632479-A2 Piperazine derivatives useful as ccr5 antagonists SCHERING CORPORATION (US) 2006-03-08 EP disclosed
EP-1175401-B1 PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS SCHERING CORP (US) 2005-07-20 EP disclosed
US-20040067961-A1 Piperazine derivatives useful as CCR5 antagonists MERCK SHARP & DOHME CORP. 2004-04-08 US disclosed
US-6689765-B2 VIRICIDES; ANTIINFLAMMATORY AGENTS SCHERING CORPORATION 2004-02-10 US disclosed
US-20030069252-A1 Piperazine derivatives useful as CCR5 antagonists MERCK SHARP & DOHME CORP. 2003-04-10 US disclosed
US-6391865-B1 AIDS THERAPY; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; SKIN DISORDERS SCHERING CORPORATION 2002-05-21 US disclosed
EP-1175401-A1 PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS SCHERING CORPORATION (US) 2002-01-30 EP disclosed
WO-2000066558-A1 PIPERAZINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS SCHERING CORPORATION (US) 2000-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069252-A1 Piperazine derivatives useful as CCR5 antagonists CCR5, CCR2, CXCR3 CYP3A4 914/4885ACHE 4277/4885KDM4E 4257/4885
US-20080069968-A1 Photocrosslinkable Materials PARG, VSIR, IGLV6-57 CYP3A4 4677/4885ACHE 3595/4885KDM4E 844/4885
US-20040067961-A1 Piperazine derivatives useful as CCR5 antagonists CCR5, CCR2, CXCR3 CYP3A4 914/4885ACHE 4277/4885KDM4E 4257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.